Poor Pfizer. Their PR people are busy at the moment. Here is the full IDEAL study:
http://jama.ama-assn.org/cgi/content/full/294/19/2437
So, what to make of it?
Firstly, the city analysts have already cut their sales estimates for Lipitor next year, anticipating that these results will cause some shift toward generic simvastatin.
In the UK there is already evidence of wholesale switching to simvastatin 40mg by practices and even of GPs being paid incentives by their employers (known as PCTs) to do so.
Secondly, Merck are running a big comparison of Vytorin to Zocor right now.
Finally. I would refer you to Mike at Pharma Watch:
http://pharmawatch.blogspot.com/2005/11/cardiologists-on-message-for-pfizer.html#comments
No comments:
Post a Comment